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ABSTRACT
Doxorubicin (Doxo) is one of multiple anthracycline drugs used to effectively treat
various forms of cancer. Unfortunately, Doxo treatment, as a side effect, induces
cardiomyopathy and subsequent heart failure. We have previously demonstrated that
transplanted embryonic stem (ES) cells and their conditioned medium (CM) modulate the
PTEN pathway and reduce apoptosis, fibrosis and hypertrophy in a Doxo induced
cardiomyopathy (DIC) model. However, mechanisms of inhibited apoptosis mediated
through PTEN pathway are completely unknown. Therefore, we used VO-OHpic (VO), a
potent PTEN inhibitor to understand the mechanism of apoptosis as well as its effect on
cardiac remodeling in DIC. Animals were divided into three groups; Group 1: Control
(Saline), Group 2: Doxo (12 mg/kg, cumulative dose) and Group 3: Doxo+VO (30ug/kg
cumulative dose). Animals were studied at one week and eight weeks post-DIC. Mice
were subjected to echocardiography to examine cardiac function, sacrificed and hearts
were harvested for further analysis. Immunohistochemistry staining revealed a significant
(p < 0.05) decrease in apoptotic cardiomyocytes in Doxo+VO treated hearts compared
with Doxo group. Furthermore, Hematoxylin and Eosin (H&E) and Masson’s Trichrome
histological stains confirmed reduced hypertrophy and fibrosis in Doxo+VO treated
subjects compared to Doxo group. Western Blotting confirmed the reduction of p-PTEN
levels and the increase in p-AKT cell survival protein expression in Doxo+VO subjects. In
addition, VO-OHpic administration was shown to reduce the number of pro-inflammatory
macrophages and increase the number of anti-inflammatory M2 macrophages that may
further be involved in reduced apoptosis and fibrosis. Finally, heart function was improved
in mice treated with VO compared to Doxo group. Collectively, our data suggests that
iii

VO-OHpic treatment reduces apoptosis, cardiac fibrosis and the process is mediated
through the PTEN/AKT and inflammatory mechanisms with improved heart function in the
DIC heart.
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CHAPTER 1: INTRODUCTION
Doxorubicin Induced Cardiomyopathy
Doxorubicin (also termed Adriamycin) is an anti-cancer drug widely used for a
variety of cancer therapies. As of June 2016, there are over 550 open trials worldwide
exploring doxorubicin usage or usage of one of its variants daunorubicin or idarubicin
(ClinicalTrials.gov). Unfortunately, clinical applications are limited due to the severe,
dose-dependent cardiotoxic events that can occur as a side effect. These events may
contribute to the development of Doxorubicin-Induced Cardiomyopathy (DIC) and
congestive heart failure. DIC is characterized by contractility and rhythmic dysregulation
as well as restructuring of the heart tissue (Singal, Iliskovic, Li, & Kumar, 1997; Minotti,
Menna, Salvatorelli, Cairo, & Gianni, 2004).
DIC is the result of multiple, interconnected complex disease mechanisms;
unfortunately, at this time, the exact mechanisms are still being researched. Some
proposed mechanisms of action include the regulation of reactive oxygen species and
antioxidants, myofibril/muscle degradation and changes in genetic expression (Singal &
Iliskovic, 1998; Chatterjee, Zhang, Honbo, & Karliner, 2010). DIC results in physiological
changes to the heart, especially the left ventricle, ultimately resulting in reduced heart rate
and impaired cardiac function. In addition, the heart will undergo physical, structural
changes, through a series of adverse events that are collectively known as cardiac
remodeling.
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Cardiac Remodeling
Cardiac remodeling is classified by a series of multiple events that occur to and
within the heart during tissue damage. A normal, healthy heart is comprised of compact
cardiomyocytes that beat in synchrony to allow for blood to rush into either the lungs for
oxygenation or to the rest of the body through the aorta. A remodeling heart will under
apoptosis (cell death) of cardiomyocytes and subsequently stimulate inflammation.
Monocytes, in particular, will travel to the site of injury and undergo reprogramming into
either pro-inflammatory M1 macrophages or anti-inflammatory M2 macrophages. In fact,
the balance of M1:M2 macrophages is viewed as a determination factor for severity of
inflammatory pathologies (Fujiu, Wang, & Nagai, 2014).
Hereafter, existing cardiomyocytes will undergo hypertrophy (cell size expansion)
in order to maintain muscular foundation of the heart. In addition, fibrosis (collagen
synthesis) will commence in order to provide additional structural support. Our lab has
previously shown collagen build-up within the heart between muscle and around arteries
and documented an increased expression of MMP9, a mediator of extracellular matrix
decomposition and subsequent fibrosis accumulation (Merino & Singla, 2014; Singla,
2015). Collectively, due to the apoptosis of cardiomyocytes, hypertrophy of existing cells
and accumulation of collagen, the newly remodeled heart’s function diminishes, ultimately
resulting in congestive heart failure or stimulate development of another cardiovascular
disease.
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Our lab has previously evaluated different mechanisms at which doxorubicin
stimulates cardiac remodeling, as shown here (Singla, Ahmed, Singla, & Yan, 2012;
Merino & Singla, 2014; Singla et al., 2012; Singla & Abdelli, 2015).

VO-OHpic
VO-OHpic is a vanadium based compound that has been established in literature
as the most potent known inhibitor of the cell death protein PTEN (Phosphatase and
Tensin Homolog) (Rosivatz et al., 2006). Vanadium mimics phopshoesters and
phosphates, allowing them to effectively inhibit phosphatases (Rosivatz et al., 2006).
Recently, VO-OHpic has been evaluated as a potential therapeutic for cardiovascular
diseases. Zu et al reported that VO administration in a myocardial infarction model to
have reduced infarction size and improve cardiac function post ischemia-reperfusion (Zu,
Shen, Wesley, & Cai, 2011). A separate study conducted by Li et al demonstrated how
VO-OHpic administration prolongs survival and improves cardiac function in a mouse
sudden cardiac arrest model (Li et al., 2015). Recent studies have supported the idea of
VO-OHpic use in diseased heart and cardiovascular tissues to improve cell survival, as
evidenced by the upregulation of p-AKT both in vivo (Zu et al., 2011; Li et al., 2015) and
in cardiac tissues in vitro (Zhu et al., 2014). p-AKT is the phosphorylated version of AKT,
an essential protein found within the PTEN-PI3K pathway.

PTEN-PI3K Pathway
The PTEN-PI3K pathway is an essential cell survival and inflammatory pathway.
This pathway has been shown to influence the release and activation of pro- and antiinflammatory cytokines. PTEN functions to dephosphorylate PIP3, which prevents the
3

phosphorylation of PI3K, subsequent activation of AKT and ultimately inhibiting cell
survival. The converse also occurs; if PTEN is inactive, PI3K is phosphorylated, thus
phosphorylating AKT and other downstream proteins to stimulate cell survival. Our lab
has previously shown the increase of p-PTEN and subsequent decrease of p-AKT in
cardiac diseases (Merino & Singla, 2014; Singla, 2015; Yan, Singla, Abdelli, Singal, &
Singla, 2013). The PI3K-AKT pathway has also shown to be influential in the polarization
of monocytes, driving them away from becoming pro-inflammatory M1 macrophages and
instead becoming anti-inflammatory M2 macrophages (Rocher & Singla, 2013).
The benefits of stem cell based therapeutics in driving cell survival have been
shown in a DIC model (Singla, 2015; Singla et al., 2012), however the potential efficacy
of the PTEN inhibitor VO-OHpic has not been explored.

Hypothesis
In this current study, we hypothesize that:
I.

Intraperitoneal (IP) delivery of VO-OHpic blunts p-PTEN levels and protects the
heart from DIC.

II.

VO-OHpic administration promotes anti-inflammatory macrophage activity and
simultaneously decreases pro-inflammatory macrophage activity

Aims
Aim 1. Evaluate the cardioprotective effects of VO-OHpic in acute and chronic DIC.
Aim 2. Determine whether VO-OHpic influences pro- and anti-inflammatory
macrophages, in particular promote anti-inflammatory M2 macrophage activity.
4

CHAPTER 2: MATERIALS AND METHODS
Animal Model and Drug Preparation
All animal protocols were approved by the University of Central Florida Institutional
Animal Care and Use Committee as per United States National Institute of Health
guidelines. C57BL/6J male and female mice of 8-12 weeks of age were separated into
groups of 7-8 animals. Mice were administered cumulative doses of 1) saline (Control
group), 2) Doxo only (12 mg/kg) or 3) Doxo (12 mg/kg) and VO-OHpic (30ug/kg).
Solutions were administered via intraperitoneal injection (IP) every other day (i.e.
Monday, Wednesday, Friday) to achieve cumulative dose. VO-OHpic was administered
30 minutes prior to same day Doxo injections, as adapted by previous studies in literature.

TUNEL staining
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) assay
was performed as previously reported. The ventricles were embedded in increasing
ethanol dilutions (up to 100% ethanol) and subsequently blocked in paraffin. 5 micron
sections were obtained and heat fixed on microscope slides. Slides were then
deparaffinized and rehydrated using xylene, 50% xylene/50% 100% ethanol and
decreasing ethanol solutions. Slides were incubated in proteinase K (Sigma-Aldrich) at a
dose of 25 ug/ml in 100 mM Tris-HCL for 15 minutes. Thereafter, TUNEL staining was
performed according to manufacturer’s instructions. Sections incubated in TUNEL
reaction mixture for one hour and washed with 1x PBS accordingly. Finally,
VECTASHIELD mounting media with DAPI (4’, 6-diamidino-2-phenylindole) (VECTOR
Labs) was applied to identify nuclei (blue). Under an Olympus fluorescent microscope, 4
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representative regions at 20X magnification were taken and the percentage of apoptotic
nuclei (red TUNEL marker) over total nuclei. Representative images were taken using a
confocal microscope.

Immunohistochemistry staining
Ventricle slides were deparaffinized and rehydrated as previously stated for
immunohistochemistry staining. Mouse antibodies for Sarcomeric-α-actin (SAA) (Sigma
Aldrich) and inducible Nitric Oxide Synthase (iNOS) (Abcam) were stained appropriately
using MOM kit as instructions prescribe (VECTOR Labs). Slides for CD206 antibody were
incubated in 10% Goat serum and Arginase-1 antibody was incubated in 10% Donkey
serum for 1 hour. Rabbit antibody for CD206 (Abcam) and Goat antibody for Arginase-1
(Santa Cruz) were diluted in 10% goat serum or donkey serum and applied for overnight
incubation at 4⁰C. Slides were then washed with 1X PBS and incubated with appropriate
secondary for 1 hour at room temperature. Sections were counterstained with DAPI
mounting medium and analyzed. An Olympus microscope was utilized for data
quantification and a confocal microscope for representative images. Areas of atrophic
tissue were imaged for quantification of % monocytes or macrophages over the total
nuclei. One representative image from each quarter of the heart (4 regions) was
quantified for apoptotic data.

Remodeling Histological Staining
Ventricle sections were deparaffinized and rehydrated, as stated previously, prior
to Masson’s trichrome or Hematoxylin and Eosin (H&E) staining. Masson’s trichrome was
performed as previously described. In brief, sections were incubated in Bouins fixative for
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45 minutes, washed and stained with Weigert Iron Hematoxylin, Biebrich Scarlet Acid
Fuschin and Aniline Blue. H&E stain was conducted using hematoxylin, acid alcohol,
bluing reagent and eosin solutions as previously described.
Sections were mounted in permount thereafter and analyzed using a light
microscope. In Masson’s trichrome, cardiomyocytes were stained in red, nuclei in black
and fibrotic areas in blue. In H&E staining, nuclei are stained in blue/purple and
cardiomyocytes in pink. Image J software was utilized to quantify vascular fibrosis (over
vascular area) and cardiomyocyte size (mm2) at 20x magnification.

Western Blot Analysis
Heart

samples

were

prepared,

supernatants

were

collected

and

gel

electrophoresis was performed. Proteins from gels were transferred onto polyvinylidene
difluoride membranes and blocked with 5% milk. Membranes were incubated with desired
antibody (phosphorylated (p-) AKT, MMP9, p-PTEN, total PTEN and β-Actin (as loading
control)) for 3 hours at room temperature or overnight at 4⁰C. Membranes were then
washed and incubated with appropriate secondary antibody for 1 hour at room
temperature. Membranes were then washed, incubated in chemiluminescent substrate
and exposed using developing film. Band intensities were measured using ImageJ
software and represented as arbitrary units (A.U.)

Echocardiographic Analysis
At day (D) 7 and 56 post final injection, two dimensional (2D) echocardiogrpahy
was performed under 2% isoflurane via nose cone to evaluate heart function, as
previously described. In brief, M-Mode images of the left ventricle (LV) during diastole
7

and systole were visualized and recorded for measurement of LV fraction shortening (FS)
and LV ejection fraction (EF). Hereafter, animals were sacrificed under isofluorane and
confirmed using cervical dislocation. Hearts were harvested, cleansed with 1X PBS and
sectioned transversely. The top portion (atria) was kept in RNA later and the bottom
portion (ventricles) in 4% paraformaldehyde (PFA).

Statistical Analysis
Statistical analysis was conducted using one-way analysis of variance (ANOVA)
and Tukey Test thereafter. Data values are presented as a mean ± SEM with p-value
<0.05 to show statistical significance between groups.
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CHAPTER 3: RESULTS
Effect of VO-OHpic treatment on apoptotic nuclei in the heart
To confirm the effects of VO-OHpic treatment on total apoptotic nuclei, a TUNEL
stain was performed. Positive TUNEL cells are quantified as red marker overlaying the
blue stained nuclei (DAPI). The number of apoptotic nuclei increased in the Doxo group
compared to the control group in both time points (Figure 1). However, the Doxo+VO
group had a significantly lower percentage of apoptotic nuclei in both time points
compared to Doxo group.

Figure 1: Percentage of Apoptotic Nuclei following Doxorubicin administration
Panels A and B display apoptotic nuclei in D7 and D56 mice hearts, respectively. Bar
Graph C (Middle of image) depicts quantification of the percentage of apoptotic nuclei
over total nuclei. *p<0.05 vs Control, #p<0.05 vs Doxo, Scale Bar = 100um, N = 5-6.
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VO-OHpic treatment reduces percentage of apoptotic cardiomyocytes
Once it was confirmed that VO-OHpic treatment reduces total apoptotic nuclei, a
second TUNEL stain was performed with the addition of the antibody for SAA in order to
quantify the percentage of apoptotic cardiomyocytes. TUNEL were stained as described
above and SAA in green. The percentage of apoptotic cardiomyocytes increased in
animals receiving Doxo treatment (Figure 2). In comparison, Doxo+VO animals have a
significantly lower amount of apoptotic cardiomyocytes, when compared to Doxo group.
Collectively with the first TUNEL stain, it can be said that VO-OHpic administration
reduces the number of apoptotic nuclei and cardiomyocytes in a DIC animal heart.

Figure 2: Apoptotic Cardiomyocytes following Doxorubicin and VO-OHpic treatment
Panels A and B display apoptotic cardiomyocytes in D7 and D56 mice hearts,
respectively. Bar Graph C (Middle of image) depicts quantification of the percentage of
apoptotic cardiomyocytes over total nuclei. *p<0.05 vs Control, #p<0.05 vs Doxo, Scale
Bar = 100um, N = 5-6.

10

Expression of Cell Survival proteins following VO-OHpic treatment
Western Blotting approaches were combined with staining data to confirm the
underlying molecular mechanisms. Western Blotting was performed to measure the levels
of proteins p-PTEN, PTEN and p-AKT upon administration of Doxo and the potential
therapeutic effects of VO-OHpic (Figure 3). The expression of p-PTEN increased upon
Doxo administration, whereas the Doxo+VO group exhibited decreased p-PTEN
expression. PTEN expression was shown to be similar in all groups, revealing that VOOHpic administration enacts on PTEN by inhibiting its ability to become phosphorylated.
In contrast to p-PTEN results, cell survival protein expression of p-AKT was reduced in
the Doxo only group and increased in the Doxo+VO group. This confirms that phosphates
available are being uptaken by the PI3K-AKT pathway to stimulate cell survival activity,
rather than being uptaken by the cell death protein PTEN.

Figure 3: Effects of Doxorubicin and VO-OHpic treatments on cell survival protein
expression.
Western Blotting of phosphorylated PTEN (A), PTEN (B) and phosphorylated AKT (C).
Results quantified in Arbitrary Units (A.U.) based on protein expression. *p<0.05 vs
Control, N = 4-7.
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VO-OHpic administration decreases fibrosis in the heart
To confirm that VO-OHpic is involved in other physiological remodeling
procedures, in addition to reduced apoptosis, Masson’s Trichrome staining was
performed to quantify the presence of collagen as a result of a remodeled heart (Figure
4A-B). Upon Doxo administration, the percentage of vascular fibrosis was shown to
increase when compared to a control, healthy heart. In contrast to Doxo hearts, Doxo+VO
animals demonstrated reduced amounts of vascular fibrosis in both time points. As further
confirmation of reduced fibrotic activity, Western Blotting for MMP9, a mediator of
extracellular matrix degradation and subsequent fibrosis, was performed (Figure 4C). In
Doxo group, the expression of MMP9 increased compared to control. In the Doxo+VO
group, however, MMP9 expression decreased in both time points. Collectively, these
results show that VO-OHpic administration reduces fibrotic activity within the murine DIC
heart.

Figure 4: Fibrosis within the heart upon Doxorubicin and VO-OHpic treatments
Panel A displays Vascular Fibrosis within the murine heart. Bar Graph B represents
quantitiative data of % Vascular Fibrosis over total Vascular Area. MMP9 expression
shown to increase in Doxo animals, but decrease with VO-OHpic co-treatment (C).
*p<0.05 vs Control, #P<0.05 vs Doxo, 20x Magnification enlarged to show artery, N = 56.
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Hypertrophy of Cardiomyocytes decreases with VO-OHpic treatment
Previous studies have shown that cardiomyocyte size expands during cardiac
remodeling. To confirm whether VO-OHpic treatment reduces hypertrophy in the DIC
heart, Hematoxylin and Eosin (H&E) staining was performed (Figure 5). Cardiomyocyte
size was shown to increase in animals with Doxo treatment compared to control hearts.
In contrast, VO-OHpic administration resulted in a lower overall cardiomyocyte size when
compared to Doxo hearts. When paired with previously stated apoptosis and fibrosis
data, it can be confirmed that VO-OHpic reduces anatomical structural changes that occur
in the heart as a result of Doxorubicin treatment.

Figure 5: Hypertrophy of heart undergoing DIC treatments
Panel A represents areas of H&E stained cardiac tissue. Bar Graph B reflects average
size of cardiomyocyte within the heart. Hypertrophy is reduced in both the D7 and D56
animals. *p<0.05 vs Control, #P<0.05 vs Doxo, 20x Magnification enlarged areas, N = 56.
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Doxo+VO reduces M1 Macrophage activity and increases M2 Macrophage activity
Monocytes have been well documented as cells with the ability to differentiate
into M1 pro-inflammatory or M2 anti-inflammatory Macrophage sub populations. To
confirm whether VO-OHpic treatment influenced M1 Macrophage populations,
immunohistochemistry staining was performed (Figure 6). iNOS (inducible Nitric Oxide
Synthase) was utilized as a marker of positive M1 Macrophages. In the Doxo animals,
the expression of iNOS positive cells/M1 Macrophages increased. In comparison, iNOS
levels were reduced in Doxo+VO hearts.
M2 macrophages were evaluated to confirm the presence of anti-inflammatory
cell activity in the heart. The markers of CD206 and Arginase-1 were stained for using
immunohistochemistry techniques and quantified for the presence of M2 macrophages
within the heart (Figure 6). The Doxo+VO hearts exhibited an increased number of M2
macrophages compared to Doxo animals. Collectively, it can be concluded that VOOHpic administration stimulates anti-inflammatory activity within the heart by driving
monocytes from M1 macrophage differentiation towards M2 macrophage differentiation.

Figure 6: Doxo+VO effects on Macrophages
Bar graphs show the presence of iNOS positive M1 pro-inflammatory macrophages (A)
and M2 Macrophages Arginase-1 (B) and CD206 (C) in D7 and D56 animals. *p<0.05 vs
Control, #p<0.05 vs Doxo, N = 4-6.
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VO-OHpic treatment improves cardiac function
Prior to sacrifice, animals were subjected to echocardiography to evaluate
function of the left ventricle as a result of doxorubicin treatment. In particular, two
functional parameters, fractional shortening (FS) (measurement of contractility) and
ejection fraction (EF) (measurement of blood ejection into heart) were quantified
(Figure 7). In Doxo animals, both functional parameters were decreased. Indicative of
reduced cardiac function. In contrast, Doxo+VO animals had significantly increased FS
and EF compared to Doxo animals, resulting in improved left ventricular function and
overall cardiac function.

Figure 7: Cardiac function improves with VO-OHpic co-treatment
Echocardiography results were measured using fractional shortening (A) and ejection
fraction (B). *p<0.05 vs Control, #p<0.05 vs Doxo, N = 6-7.
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CHAPTER 4: DISCUSSION
Due to PTEN’s catalytic pocket and elliptical opening, it makes it unique from other
cysteine-based phosphatases, such as tyrosine phosphatases. As a result, VO-OHpic’s
structure and composition would fit nicely into this active site (Rosivatz et al., 2006). In
comparison to other phosphatases, VO-OHpic’s structure may be too large for their active
sites. It is possible that due to the binding of the VO-OHpic with the PTEN active site, it
allows for phosphates to become more accessible to proteins such as AKT and PI3K,
thus leading to activation and the progression of survival mechanisms. In addition, VOOHpic has been shown to be non-competitive in nature (with respect to OMFP substrate,
a substrate used in PTEN inhibition studies) (Mak, Vilar, & Woscholski, 2010)as well as
a reversible inhibitor (Mak et al., 2010; Spinelli, Lindsay, & Leslie, 2015), making it ideal
in therapeutic design in order to optimize treatments for a desired pathology.
Collectively, Immunohistochemistry, Masson’s Trichrome and H&E stainings
experiments confirmed the progression of cardiac remodeling in doxorubicin animals
through apoptotic, fibrotic and hypertrophic mechanisms at both an acute stage (D7) and
chronic/long-term stage (D56) post treatment. In comparison, when doxorubicin was
combined with VO-OHpic, the amount of cardiac remodeling events within and of the
heart decreased. To further validate the physiological events, western blotting was
performed to examine cell survival proteins essential to the cardiac remodeling process,
in particular phosphorylated/active forms of PTEN and AKT. With co-treatment, p-PTEN
expression decreased in Doxo+VO animals and p-AKT expression increased.
In addition to physical changes to the heart, inflammatory cells essential to cardiac
remodeling were evaluated. Monocytes and macrophages, important in the phagocytosis
16

of debris and the secretion of appropriate cytokines and factors, were identified and
studied for additional confirmation of VO-OHpic’s effects within the heart. VO-OHpic
animals demonstrated reduced volumes of positive M1 pro-inflammatory macrophages
and increased volumes of M2 anti-inflammatory macrophages. To further confirm the
beneficial effects of VO-OHpic administration on inflammatory actions in the heart,
additional interleukins and cytokines should be evaluated.
Recently, the inflammatory role of T cells have been a subject of interest in the
inflammatory and cardiovascular field as potential mediators of cardiovascular disease
development. Naïve T cells can be converted into pro- or anti-inflammatory sub
populations and can secrete factors known to play important roles inflammation (i.e.
recruiting or stimulating cell activity (Meng et al., 2016). Our preliminary data has shown
that VO-OHpic in the DIC heart increases anti-inflammatory T cell activity (data not
shown), which may promote cell survival and M1 to M2 macrophage differentiation.
Additional studies will be necessary to further elucidate the effects of VO-OHpic on T cell
activity.
In conclusion, this study demonstrates that treatment with VO-OHpic reduces
doxorubicin induced cardiomyopathy, as evidenced by a reduction in cardiac remodeling
events and an increase in cell survival protein activity. In addition, our data suggests a
polarization of monocytes from pro-inflammatory M1 macrophages to anti-inflammatory
M2 macrophages.
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